3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Thyroid Carcinoma, Anaplastic
2
Skin Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid cancer, follicular
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
atezolizumab
1
alectinib
1
Vemurafenib
1
Fruit
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genomic Instability
×
Vemurafenib
×
1 year
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled